The price of Medical Marijuana Inc (OTCMKTS:MJNA) has been on the rise over the past few days. During this period, the share price has risen from trading below $.10 to $.155. Furthermore, the traded volumes also rose to over 50 million within the same period.
This share price action can be seen below:
With this being the case, we have chosen to take a closer look at MJNA and establish their value addition proposition.
MJNA: A Brief
Medical Marijuana Inc (OTCMKTS:MJNA) is the first publicly held company vested in the cannabis and industrial hemp space in America. Through its subsidiaries and investment holdings, the company focused on the development, sale and distribution of hemp that contains naturally occurring cannabinoids including cannabidiol (CBD) and other products containing CBD-rich hemp oil (legal hemp). The company was incorporated in 2005.
Company’s products are formulated for the pharmaceutical, nutraceutical and cosmeceutical industries including dietary supplements. Prescription-based hemp oil for sale in countries that have legalized their hemp oil for the treatment of various illnesses and conditions (such as Brazil and Mexico) and skin care products.
The company isn’t in the business of selling or dispensing either recreational or medical marijuana directly or indirectly so long as marijuana remains a federally controlled substance. However, they are well positioned for eventual Federal cannabis legalization.
The company continues to be an industry leader and feels that the future is bright.
Mexico and Cannabis
During our last review of the company, which can be accessed here, we assessed how the company’s geographical expansion was going to boost them. Back then, they had ventured into Mexico and delivered a girl to from her seizures. They then went on to grow their brand there as well as opened some subsidiaries.
HempMed@Mexico, one of their subsidiaries, is a Mexico-based company that made history by being the first company to receive a COFEPRIS federal government import permit for the cannabis product RSHO-X for a medical indication. The company plans to work directly with the Mexican government to safely and legally provide access to CBD hemp oil products.
On 18th December, the company announced the promotion of the CEO of HempMed@Mexico, Blake Schroeder as the Chief Operating Officer of Medical Marijuana. He had previously served as Vice President of Operations. However, he still retains his position as the CEO of HempMed@Mexico.
Schroeder has a wealth of experience, having served in various capacities in different companies and driving the direct international sales docket the nutritional industry. He is therefore no newcomer in the marketing world. He joined the company in 2016.
The CEO of Medical Marijuana was upbeat that Mr Blakes promotion would being a major turnaround in the group’s overall growth and market potential. On his part, Mr Blake said that he is excited about his promotion especially in today’s challenging marketing world. Worth noting is that the subsidiary which Mr Blake was leading announced its largest ever revenue month in the history of the company and the launch of several new products.
Medical Marijuana announced on 13th November that its subsidiary Kannaway LLc, the first hemp lifestyle network to offer cannabidiol, hemp botanical products is recognizing its second pair of brand ambassadors to reach the presidential elite rank.
Randy and Samantha Schreuder have achieved presidential elite status which requires achieving a minimum of $700,000 in sales per month. They have in the past been recognized several times for their efforts to educate others about Kannaway@cannabidiol (CBD) hemp oil products.
Mr Blake Schreuder praised the pair for their commitment and drive in their endeavours for success which has seen the company gain a foothold in market penetration. Kannaway specializes in the same of hemp-based botanical products.
The company hosts weekly online sales meetings and conferences across the United States, offering unique insight and opportunity to sales professionals who wish to become successful leaders in sale and marketing of hemp-based botanical products.
The WHO and Cannabis
Further information released by the company was an announcement to the effect that Raul Elizalde, President of a subsidiary, HempMeds@Mexico was recently featured in several international news publications about his speaking engagement at the World Health Organization (WHO) Drug Scheduling convention in November 2017.
Raul whose campaign to help his epileptic daughter legalized cannabidiol in Mexico, discussed how the substance is non-psychoactive, non-addictive and has no negative side effects. He shared his story about how CBD changed his family’s life for the better and how the WHO’s recommendation has the potential to change many more lives across the globe.
Research shows that CBD may not be abused or create dependency. A comprehensive review of cannabis will be conducted in 2018 according to WHO.
It is the feeling of the company’s management that Raul’s representation is a matter of pride to them. Their CEO put across an argument that CBD has therapeutic properties and value for conditions such as seizures due to epilepsy and related conditions.
MJNA have their mission of increasing access to CBD featured in coverage on prominent media outlets. Their CEO, Dr Stuart Titus believes that Raul had a significant impact on the WHO’s recommendation not to schedule CBD. He said he is thankful to the media which continues to view Raul as an important cannabis industry icon.
To sum it all up, on December 14, the company announced that the WHO has made the expert recommendation not to schedule cannabidiol as a drug. This was a major breakthrough for the company which waits for a further scrutiny of this product to be conducted and results released in 2018.
Coupled with product diversification, this might be a game changer in the company’s growth.
We will be updating our subscribers as soon as we know more. For the latest updates on MJNA, sign up below!
Disclosure: We have no position in MJNA and have not been compensated for this article.